Objective: To investigate the effect of pitavastatin on asymptomatic atherosclerosis in patients with hypercholesterolemia. Methods: Thirty-five outpatients with hypercholesterolemia (61.5 12.8 yr) were administered 2 mg oral pitavastatin daily for 6 months. Plasma pentraxin 3 (PTX3), a novel inflammatory marker of atherosclerosis, was measured together with the serum hsCRP and carotid-artery intima-media thickness (IMT). Results: Significant improvement of the LDL-C/HDL-C and log (TG/HDL-C) ratios began to be observed from 1 month after using pitavastatin. Significant correlation of the initial PTX3 value was observed with the initial plaque score (PS) (p 0.038, r 0.246), but not between the hsCRP and plasma PTX3 or PS. When patients were divided into 3 groups based on the initial PTX3 values, a significant decrease of the plasma PTX3 was obtained in the highest PTX3 group alone (p 0.034). The change in the plasma PTX3 value ( PTX3) was significantly correlated with the mean IMT during the study period (p 0.008, r 0.456). Conclusion: Pitavastatin significantly reduced the elevated plasma levels of PTX3 in patients with hypercholesterolemia by its pleiotropic effect against atherosclerotic inflammation. This study showed for the first time that the plasma PTX3 might be a useful blood parameter for direct detection of active atherosclerotic change. 
lar events and cardiovascular mortality 1) . A recent retrospective study involving intravascular ultrasound (IVUS) analyses demonstrated a significant reduction of the plaque volume index in subjects treated with pitavastatin (2 mg/day) as compared with the control group 2) . The existence of a positive correlation has been reported between the percent change in the plaque volume index and the change of the serum LDL-C level following pitavastatin treatment
Introduction
Pitavastatin is a new synthetic 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor (statin) that has been available in Japan since July 2003. Besides their potent plasma cholesterol-lowering activity, HMG-CoA reductase inhibitors are also generally well-known to exert beneficial pleiotropic effects which may directly limit the development of atherosclerosis, and thereby reduce the risk of cardiovascu-Although IVUS is a good method to detect atherosclerotic plaques, this examination is not easy and is rather invasive, and cannot be performed during routine clinical follow-up. Measurement of the intimamedia thickness (IMT) of the carotid artery by ultrasonography is a well-established surrogate marker for cardiovascular diseases; however, it is relatively difficult to precisely grasp the short-term changes in atherosclerosis by this method. In addition, IMT data can be influenced by differences in individual examiners' techniques and the structural changes themselves do not always precisely reflect the prevailing status of inflammation. Atherosclerotic changes must be evaluated from both points of view, namely, structural changes and inflammatory activities; therefore, in order to limit the progression of atherosclerosis from an even earlier stage, other indices that would allow clear detection and monitoring of dynamic inflammatory changes in arterial walls are desirable.
Pentraxin 3 (PTX3), a prototypic member of the long pentraxin family, was first identified in 1992 3) . PTX3 is rapidly produced at sites of inflammation by vascular endothelial cells, smooth muscle cells, macrophages and neutrophils in response to inflammatory stimuli, while classic short pentraxin CRP is mainly synthesized in the liver 4, 5) . Plasma PTX3 is abundantly produced in acute cardiovascular diseases, such as acute myocardial infarction 6, 7) and unstable angina pectoris 8) , and also in non-ischemic chronic heart failure 9) . The plasma PTX3 levels increased significantly 15 min after elective coronary stenting, suggesting that PTX3 may be a useful marker for the evaluation of inflammatory reactions and neointimal thickening after vascular injury 10) . However, although this novel index may possibly become a valuable index for monitoring inflammatory changes in arterial walls, few studies have evaluated the levels of PTX3 in subjects with asymptomatic atherosclerosis. An in vitro study using DNA microarray analysis by Morikawa et al. demonstrated that pitavastatin suppressed PTX3 mRNA expression in cultured human umbilical vein endothelial cells and coronary artery smooth muscle cells in a dose-dependent manner 11) , which prompted us to investigate the effect of pitavastatin on plasma PTX3 levels in asymptomatic subjects with hypercholesterolemia. In this study, we have demonstrated, for the first time, that pitavastatin reduced PTX3 levels in subjects with higher baseline PTX3 levels, and revealed the relationship between the plasma PTX3 level and other conventionally used clinical markers, including the serum level of high-sensitivity C reactive protein (hCRP) and carotid artery intima-media thickness (IMT) in asymptomatic subjects with hypercholesterolemia.
Methods

Subjects
This study was carried out in accordance with the principles embodied by the Helsinki Declaration, 1995 (as revised in Edinburgh 2000). The study was approved by the ethics committees of Tohno-Kousei Hospital, and all patients gave written informed consent. The clinical significance and purpose of the study, together with the possible disadvantages of pitavastatin administration, were explained in detail to each patient. None of the patients had any current or past history of ischemic heart disease. Before enrollment in the study, we excluded patients who met the following exclusion criteria: 1) previous usage of stains; 2) taking any medication that might potentially affect the PPAR and insulin resistance, such as pioglitazone and fibrates; 3) taking medication for anti-coagulation, or anti-platelet drugs; 4) severe hepatic, respiratory or renal disease failure, hematologic diseases or other grave complications; 5) oral steroid use; and 6) a history of poor drug compliance. Other medications used before the study were allowed to be continued concurrently with pitavastatin, with the doses of these drugs being kept constant throughout the study period. The subjects enrolled in the study were 35 outpatients with untreated hypercholesterolemia who visited our hospital during a 6-month period. Hypercholesterolemia was diagnosed according to the guidelines of the Japan Atherosclerosis Society 12) . First, we divided the 35 subjects into two groups based on the findings of carotid ultrasonography: the IMT thickening group and no-IMT thickening group. In order to clarify the time course of the changes in the PTX value, we then assigned the subjects into three groups according to the initial levels of PTX3. The patient characteristics are shown in Table 1A , B.
Study Protocol
After obtaining informed consent from each participant, we started to administer oral pitavastatin at a dose of 2 mg daily. Fasting venous blood samples were obtained to measure the plasma PTX3, serum hsCRP, serum adiponectin, serum leptin and to perform routine laboratory blood tests, such as measurement of the plasma levels of cholesterol and glucose, before and 1, 3 and 6 months after the start of treatment with pitavastatin. The routine blood laboratory assays were performed using an automated analyzer (TBA-120FR; Toshiba, Tokyo, Japan) within 1 hour. Each patient's serum was immediately frozen at 70 and assayed within 24 hours. All plasma samples were kept frozen at 20 soon after sampling. We measured the plasma PTX3 values within 6 months because PTX3 is stable for repeated freeze-thaw at least for 18 months at 20 storage. PTX3 was measured with a high-sensitive human PTX3 ELISA kit (Perseus Proteomics Inc., Tokyo, Japan), for which the intra-assay and inter-assay coefficients of variation had already been confirmed in a previous study by Inoue et al. 8) . Serum levels of leptin, adiponectin and hsCRP were measured using a leptin RIA kit (Linco Research Co. Ltd., USA), adiponectin ELISA kit (Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan) and N-latex CRP kit (Dade Behring, USA), respectively. The waist circumference of the subjects (measured to the nearest 0.1 cm) was measured horizontally at the level of the umbilicus by the same trained staff. Blood pressure was measured twice after the patient had rested for at least 15 minutes and the lower of the two values was chosen. HOMA-R was used as the index of insulin resistance (a value of more than 2.5 was considered to represent insulin resistance). Bilateral carotid IMT measurements were performed by the same well-trained examiners at each of the common carotid arteries, the carotid bulb and the internal carotid artery with a high resolution B-mode ultrasonography unit (LOGIQ 9; GE Medical Systems, Wisconsin, USA) with a 12.0 MHz transducer. We defined plaque as an area with a localized IMT increase of no less than 1.1 mm. Each carotid artery was divided into four equal 15 mm-length segments and named S1 − S4 from the distal side; S1: peripheral segment 0 − 15 mm distal to the flow divider, S2: 0 − 15 mm proximal to the flow divider, S3: 15 − 30 mm proximal to the flow divider, and S4: 30 − 45 mm proximal to the flow divider. The sum of the segment numbers (S1 − S4 on the right and left sides), whose maximal IMT thickness was no less than 1.1 mm was defined as the plaque score (PS) in this study. The mean IMT was also defined as the average thickness of the eight segments. Brachial-ankle pulse wave velocity (baPWV) was measured by an automatic waveform analyzer (Form ® PMV/ABI BP-203RPE ; Omron Colin, Co. Ltd., Tokyo, Japan) after 15 minutes' rest. We determined a baPWV cutoff value of 1,400 cm/s for screening subjects at risk of developing cardiovascular disease 13) . We also measured the ankle-brachial index (ABI) together with the baPWV, and confirmed that the ABI values in each study subject were within the normal range (0.9 − 1.3). We chose the lesser value of the baPWV between the right and left sides for analyses in this study.
Statistical Analyses
The significance level was set at 5%. Routine laboratory blood data, blood pressure, BMI and waist circumference are expressed as the means SD, while the plasma PTX3, serum leptin, serum adiponectin, hsCRP and baPWV are expressed as the median and 25th to 75th percentiles. The blood pressure, BMI and waist circumference between the high PTX3 group and the other groups were compared with the unpaired t test, while the plasma PTX3, serum hsCRP, serum adiponectin, serum leptin, plaque score, IMT and baPWV were compared by the Mann-Whitney test ( Table 1) . Correlation between the initial plasma PTX3 levels and the serum hsCRP was examined by using the Spearman rank correlation, as shown in Fig. 1 . The time course of changes in the plasma PTX3 in each group (as shown in Fig. 2 ) was analyzed by the Friedman test and the Wilcoxon signed-rank test with Bonferroni's correction. The time-course of changes in the routine blood laboratory data in each group was analyzed by repeated-measures ANOVA and the Scheffé method as a post-hoc test ( Table 2) . Statistical analyses were carried out using JMP, version 5.1.2 (SAS Institute Inc., Cary, NC, USA).
Results
The study protocol was completed in all 35 subjects. No side effects were encountered during the study period.
Relationship between the Initial Plasma PTX3 Level and Other Indices at Study Entry
We first assigned the entire subject population to two groups according to the presence/absence of IMT thickening at the start of the study. No significant differences in the initial plasma PTX3 levels were observed between the IMT thickening group (n 19) and no-IMT thickening group (n 16) (p 0.274) ( Table 1A) ; however, a significant correlation was found between the initial plasma PTX3 level and the initial plaque score (PS) (n 35, p 0.038, r 0.246) ( Table 2 ). The correlation was stronger when the no-IMT thickening group was excluded from the analysis (n 19, p 0.016, r 0.475) (Fig. 1A) . Correlations between the initial plasma PTX3 level and the other indices at study entry are also shown in Table 2 . No significant correlation was found between the plasma PTX3 and the serum hsCRP (n 35, p 0.471, r 0.043) (Fig. 1B) , or between the serum hsCRP and the PS (n 35, p 0.352, r 0.135) (Fig. 1C) .
Time Course of Changes in the Various Indices Over the 6-Month Study Period
In order to clarify the time course of changes in the plasma PTX, we then assigned the entire subject population to three groups according to the initial plasma level of PTX3 (Table 1B) : ( ) high PTX3 group (n 12), ( ) intermediate PTX3 group (n 12), and ( ) low PTX3 group (n 11). As shown in Table   Table 1 1B, the initial PS values in group ( ) were significantly higher than those in groups ( ) and ( ) (p 0.045 and p 0.038, respectively), while there were no significant differences in the various indices, except PTX3, among the three groups.
As shown in Fig. 2(A) , the median (25th percentile − 75th percentile) of the plasma PTX3 decreased significantly from 2.87 (2.37 − 3.68) to 2.59 (1.98 − 2.99) one month after the start of treatment with pitavastatin, and the levels remained significantly PTX3 levels and serum hsCRP, and (C) plaque score (PS) and serum hsCRP in all subjects (n 35) and the IMT thickening group (n 19) at entry to the study.
reduced at 3 and 6 months after the start of administration in group ( ), but not in group ( ) or group ( ). On the other hand, no significant changes in the serum hsCRP were found during the 6-month study period in any of the groups (Fig. 2(B) ). The baPWV decreased significantly from 1649.0 (1387.0 − 1859.0) to 1614.0 (1397.0 − 1850.0) (p 0.041, Wilcoxon's signedrank test) during the 6-month period of treatment with pitavastatin (p 0.005, Freidman test) ( Table 3) . The time course of changes in the laboratory blood data during the 6-month period are shown in Table 3 . Significant decreases of the serum total cholesterol, LDL-C and ChE were found one month after the start of treatment and the reductions persisted throughout the study period. The LDL-C/HDL-C ratio decreased significantly from 3.00 1.41 to 2.10 0.95 one month after the start of pitavastatin treatment and persisted at a reduced level, close to 2, throughout the study period (p 0.001). A significant decrease of the logarithm of the ratio of the concentration of triglycerides to HDL-cholesterol (log (TG/HDL-C)), an atherogenic index directly related to the risk of atherosclerosis 14) was also found during the study period ( Table 3) .
Correlations Among Changes in Each Index During the Study
Correlations of the changes in each of the indices during the 6-month treatment period with pitavastatin are shown in Table 4 . Changes in the plasma PTX3 during the 6-month period ( PTX3) were significantly correlated with those of the mean IMT ( mean IMT) (p 0.008, r 0.456), particularly in the high PTX3 group.
Discussion
In this study, we demonstrated that pitavastatin significantly reduced the elevated plasma levels of PTX3 in patients with hypercholesterolemia, and also the possibility that plasma PTX3 could become a useful blood parameter for monitoring the progression of inflammatory changes in subjects with asymptomatic atherosclerosis. Although previous studies, as mentioned in the introduction, reported a remarkable elevation of plasma PTX3 in acute myocardial infarction 6, 7) , unstable angina pectoris 8) , and non-ischemic chronic heart failure 9) , this study is the first to show a significant correlation between PTX3 levels and PS values in carotid ultrasonography.
First, we divided subjects into two groups according to the presence/absence of IMT thickness at entry to the study. Although the plasma PTX3 levels were higher in the IMT thickening group, the difference in initial PTX3 levels between the IMT thickening group and no-IMT thickening group was not statistically significant. This may result from the small number of subjects in this study. As shown in Table 2 , the initial plasma PTX3 level significantly correlated with the initial PS, while initial max IMT or mean IMT values were not significantly correlated with the initial PTX3; however, PTX3 was significantly correlated with mean IMT, but not with PS and max IMT, as shown in Table 4 . This discrepancy may also result from the small number of subjects involved in this study. Both the plasma PTX3 and ultrasonographic indexes are useful markers for atherosclerosis. These ultrasonographic indexes are fundamentally reflected in the number and size of the plaque, but they cannot sufficiently describe the proinflammatory changes in early atherosclerosis. Morphological changes in IMT thickening may not always reflect proinflammatory changes in the arterial wall. On the other hand, PTX3 can directly reflect dynamic changes in vascular inflammation which do not necessarily affect IMT thickening. Although the PS and max IMT mainly represent the change in the size of plaque, these indices cannot catch early changes in the intima-media. On the other hand, as mean IMT is calculated as the average of each 4 intima-media segments of both carotid arteries, the mean IMT may more closely reflect early proinflammatory changes in the arterial wall than the two other indices; PS and max IMT. As a result, the mean IMT significantly correlates with the PTX3, as shown in Table 4 . Although atherosclerosis should be evaluated by both structural changes and inflammatory activities, the most important points in clinical practice are to detect and prevent the process of early atherogenesis. In this sense, PTX3 may become a new useful marker for atherosclerotic inflammation.
Considering that the normal range of plasma PTX3 levels in healthy volunteers is less than 2 ng/ mL, as confirmed in several previous studies 6, 8) , the initial plasma PTX3 in the high PTX3 group (n 12) was significantly elevated compared with in the other two PTX3 groups (Table 1B) . Pitavastatin was administered at a dose of 2 mg/day and the time courses of changes of various parameters were investigated. Pitavastatin significantly decreased the plasma PTX3 in the high PTX group, but not in the intermediate or low PTX3 groups (Fig. 2) , indicating that pitavastatin Table 3 . Time course changes in blood laboraory data and baPWV over 6 months could directly suppress active atherosclerotic inflammation, but did not affect plasma PTX3 levels when they were within the normal range. Pitavastatin dosedependently suppressed the PTX3 mRNA expression in human umbilical vein endothelial cells and cultured coronary artery smooth muscle cells 11) , which lends support to our results from an experimental aspect.
Although the exact mechanism underlying the beneficial anti-inflammatory effect of pitavastatin against atherosclerosis remains unclear, the results of recent studies, mentioned below, may partly explain the actions of pitavastatin. As one of the stronger statins, pitavastatin shows a strong beneficial effect on hypercholesterolemia without significant adverse effects ( Table 3 ) that may effectively lead to plaque regression. A recent study using IVUS conducted by Nicholls et al. showed that a decrease in the LDL-C to HDL-C ratio (LDL-C/HDL-C) to less than 2 during treatment with statins was associated with the greatest degree of atheroma regression 15) . The log (TG/HDL-C) is also considered an atherogenic index that is directly related to the risk of atherosclerosis 14) . Significant reductions of both the LDL-C/HDL-C and log (TG/ HDL-C) were observed during the treatment period in this study (Table 3) , which indicates a direct effect of pitavastatin in preventing atherogenic changes. Additionally, atherogenic remnant lipoproteins (RLPs) are known to induce foam cell formation from macrophages. An in vitro study demonstrated that pitavastatin inhibited RLP-induced macrophage foam cell formation, at least in part through regulation of the apoB48 receptor expression, a novel receptor for RLPs 16) . A recent study by Koshiyama et al. showed that the administration of pitavastatin significantly reduced serum remnant-like particle cholesterol (RLP-C) levels by 22.8%, together with serum LDL and hs-CRP levels 17) , which suggested that pitavastatin improved lipid profiles and prevented atherogenic changes.
Recent data by Alberti et al. showed that PTX3 is expressed and released from visceral adipose tissue probably under tumor necrosis factor alpha control 18) . In Table 2 , we also found that baseline PTX3 was significantly correlated with baseline adiponectin, an adipocytokine (p 0.045, r 0.437), which suggested that some PTX3 in this study might be released from visceral adipose tissue.
In this study, we also demonstrated a significant reduction in baPWV values. A previous study using a catheter tip mounted with a pressure manometer showed a significant correlation between the baPWV and aortic pulse wave velocity 13) . The baPWV was significantly higher in patients with coronary artery disease (CAD) than in non-CAD patients with risk factors, and higher in non-CAD patients with risk factors than in healthy subjects without risk factors. Although few studies have shown reduction of baPWV with pitavastatin treatment, several previous studies have demonstrated this effect for other statins. Yokoyama et al. showed that fluvastatin treatment at 40 mg daily for 12 months produced a significant decrease of PWV 19) . On the other hand, Ozaki et al. reported that atorvastatin treatment at 10 mg daily significantly reduced hsCRP at 6 months, but had no significant effect on baPWV 20) . A comparative study among pravastatin, simvastatin and fluvastatin showed that although serum hsCRP levels decreased significantly in all three statin groups, the effects on PWV differed among the three drugs after a 12-month treatment period: PWV showed no change in the pravastatin group, was transiently reduced in the simvastatin group, and was significantly decreased in the fluvastatin group 21) . These results show different degrees of the effects of different statins on PWV. In this study, we demonstrated a significant reduction of baPWV following pitavastatin treatment at 2 mg/day for 6 months.
Finally, as the accurate mechanism of PTX3 in atherosclerosis is still under investigation, PTX3 has been shown to upregulate tissue factor expression in human endothelial cells 22) , suggesting that PTX3 may stimulate the onset of acute coronary syndrome. On the other hand, a recent study has shown that PTX3 protects against tissue damage in an experimental animal model of acute myocardial infarction 23) . This study is the first to report the time course of the preventative effect of pitavastatin against asymptomatic atherosclerosis in subjects with hypercholesterolemia, and it suggested that plasma PTX3 might be a useful blood parameter to understand the dynamics of inflammatory changes in active atherosclerosis progression. These new findings may serve as the basis for a novel therapeutic strategy for limiting active atherogenic inflammation before the development of fullblown atherosclerosis.
